Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.
Also called NCT07077525
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 196 participants
- Sponsor
- Al-Azhar University
- Registry
-
NCT07077525
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT07077525. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (actual); primary completion 2024-08-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors
- Condition
- Type 2 Diabetes
- Intervention (Combination product)
- Dapagliflozin + Metformin
- Intervention (Combination product)
- Vildagliptin + Metformin
- Lead sponsor
- Al-Azhar University
- Collaborator
- General Committee of Teaching Hospitals and Institutes, Egypt
Record details
- Record id
cardio:ct-nct07077525- Content hash
6cb7c1bca31d06618a46f295c63729c56cfd4e6ac3eef91793596e89796a6f16